Tada,

Thanks so much for your report of the Q&A from the Zenith AGM.

Regarding the excitement about slide 17, I have split excitement/concern. While the first 3 patients in Cohort 2 are rock stars that are past the 32 week mark, 2 of the other 3 patients had progression around week 11. And, in the Cohort 3, 2 of the 4 patients had progression around week 11. I know during the presentation DM talked about the need to find out why some patients are responding and others aren't. But was there any discussion during the Q&A about concerns surrounding non-responders?

Very interesting about the "pre-IPO" private placement. As you noted, more clarity is needed regarding whether this potential IPO is for ZCC and/or ZEL. Hopefully around the time of Biotech Showcase/JPM next month more clarity will be communicated.

Best regards,

BearDownAZ